HC Wainwright & Co. Reiterates Buy on Immunovant, Maintains $29 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Douglas Tsao has reiterated a 'Buy' rating on Immunovant (NASDAQ:IMVT) and maintained a $29 price target.
August 11, 2023 | 5:02 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Immunovant's stock rating has been reiterated as 'Buy' by HC Wainwright & Co. with a maintained price target of $29.
The reiteration of a 'Buy' rating by a reputable analyst like Douglas Tsao from HC Wainwright & Co. is a positive signal for Immunovant. The maintained price target of $29 also indicates confidence in the company's future performance. This could potentially lead to an increase in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100